In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002) - PubMed (original) (raw)
Affiliations
- PMID: 10741711
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002)
L Hu et al. Clin Cancer Res. 2000 Mar.
Abstract
Phosphatidylinositol 3-kinase (PI3-K) induces mitogenesis, cell growth, and cell transformation. Amplification of the gene encoding the P110alpha subunit likely is an important event in ovarian cancer progression, and PI3-K inhibitors are possible therapeutic agents for this disease. We evaluated effects of LY294002, a potent inhibitor of PI3-K, on growth of ovarian carcinoma in vivo and in vitro, and on ascites formation in vivo. Athymic mice were inoculated i.p. with the ovarian cancer cell line OVCAR-3. Seven days after inoculation, mice were treated with or without LY294002 (100 mg/kg of body weight) for 3 weeks. Body weight and abdominal circumference were measured twice weekly. At the end of the experiment, mice were sacrificed, ascites volume was measured, and tumors were excised. Mean tumor burden in the LY294002-treated group was reduced by approximately 65% versus controls. Virtually no ascites developed in the treatment group; mean volume of ascites in controls was 3.3 +/- 0.38 ml. OVCAR-3 cells also were cultured in vitro without and with LY294002 (1, 5, and 10 microM) for 24 h. The number of cells in 1, 5, and 10 microM LY294002-treated wells was reduced by 27, 56, and 75%, respectively, versus controls. In vivo and in vitro morphological studies demonstrated that LY294002 induced marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells, confirmed as apoptosis. Thus, LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma in vivo and markedly inhibits ovarian cancer cell proliferation in vitro, suggesting an important role of PI3-K inhibitors as a potentially useful treatment for women with ovarian carcinoma.
Similar articles
- Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Hu L, et al. Cancer Res. 2002 Feb 15;62(4):1087-92. Cancer Res. 2002. PMID: 11861387 - Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Hu L, Hofmann J, Jaffe RB. Hu L, et al. Clin Cancer Res. 2005 Nov 15;11(22):8208-12. doi: 10.1158/1078-0432.CCR-05-0206. Clin Cancer Res. 2005. PMID: 16299254 - [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren Y, Zha X, Zhang GN. Ren Y, et al. Zhonghua Yi Xue Za Zhi. 2007 May 8;87(17):1204-6. Zhonghua Yi Xue Za Zhi. 2007. PMID: 17686243 Chinese. - [Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth].
Stahl U, Wenk J, Wagener F, Woenckhaus J, Gamerdinger U, Battmann A, Dreyer T. Stahl U, et al. Pathologe. 2004 Feb;25(1):31-7. doi: 10.1007/s00292-003-0673-2. Pathologe. 2004. PMID: 14767610 Review. German. - Growth factors in human ovarian cancer.
Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S. Westermann AM, et al. Cancer Treat Rev. 1997 Mar;23(2):113-31. doi: 10.1016/s0305-7372(97)90024-4. Cancer Treat Rev. 1997. PMID: 9225962 Review. No abstract available.
Cited by
- Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells.
Wempe SL, Gamarra-Luques CD, Telleria CM. Wempe SL, et al. Cancer Growth Metastasis. 2013;6:1-13. doi: 10.4137/CGM.S11124. Epub 2012 Jan 28. Cancer Growth Metastasis. 2013. PMID: 23420486 Free PMC article. - VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway.
Yamaguchi R, Harada H, Hirota K. Yamaguchi R, et al. Tumour Biol. 2016 Oct;37(10):13295-13306. doi: 10.1007/s13277-016-5260-2. Epub 2016 Jul 26. Tumour Biol. 2016. PMID: 27460078 Free PMC article. - Potential relationship between Sirt3 and autophagy in ovarian cancer.
Shi Y, He R, Yang Y, He Y, Zhan L, Wei B. Shi Y, et al. Oncol Lett. 2020 Nov;20(5):162. doi: 10.3892/ol.2020.12023. Epub 2020 Aug 26. Oncol Lett. 2020. PMID: 32934730 Free PMC article. Review. - Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice.
Xing CG, Zhu BS, Fan XQ, Liu HH, Hou X, Zhao K, Qin ZH. Xing CG, et al. World J Gastroenterol. 2009 Oct 28;15(40):5044-52. doi: 10.3748/wjg.15.5044. World J Gastroenterol. 2009. PMID: 19859997 Free PMC article. - A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
Hu C, Raja Solomon V, Cano P, Lee H. Hu C, et al. Eur J Med Chem. 2010 Feb;45(2):705-9. doi: 10.1016/j.ejmech.2009.11.017. Epub 2009 Nov 11. Eur J Med Chem. 2010. PMID: 19945197 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical